home / stock / mdna:cc / mdna:cc news

MDNA:CC News and Press, Medicenna Therapeutics Corp. From 11/09/23

Stock Information
Company Name: Medicenna Therapeutics Corp.
Stock Symbol: MDNA:CC
Market: TSXC
Website: medicenna.com
Menu
MDNA:CC MDNA:CC Quote MDNA:CC Short MDNA:CC News MDNA:CC Articles MDNA:CC Message Board
Get MDNA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
MDNA:CC - Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and a...
MDNA:CC - Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R ⍺ 2 targeted therapy that delivers ...

MDNA:CC - Expected Canadian Company Earnings on Friday, November 3rd, 2023

Oncolytics Biotech Inc. (ONC:CA) is expected to report $-0.1 for Q3 2023 Enbridge Inc. (ENB:CA) is expected to report $0.59 for Q3 2023 Magna International Inc. (MG:CA) is expected to report $1.86 for Q3 2023 Laramide Resources Ltd. (LAM:CA) is expected to report for Q2 2024 Ensig...

MDNA:CC - Expected earnings - Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. (MDNA:CA) is expected to report $-0.06 for Q2 2024
MDNA:CC - Medicenna Announces Nasdaq Delisting and Cutback of Management Team

TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received ...

MDNA:CC - Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 do...

MDNA:CC - Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer's (SITC)

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38 th Annu...
MDNA:CC - Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphr...

MDNA:CC - Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologically “hot ...

MDNA:CC - Medicenna Announces Results of Annual and Special Meeting of Shareholders

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results fro...
Previous 10 Next 10